These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6333775)

  • 1. Penetration of erythromycin in respiratory tract infections.
    Walstad RA; Hellum KB
    Acta Otolaryngol Suppl; 1984; 407():50-4. PubMed ID: 6333775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacological evaluation of different preparations of oral erythromycin.
    Butzler JP; Vanhoof R; Clumeck N; de Mol P; Vanderlinden MP; Yourassowsky E
    Chemotherapy; 1979; 25(6):367-72. PubMed ID: 316377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.
    Peters DH; Friedel HA; McTavish D
    Drugs; 1992 Nov; 44(5):750-99. PubMed ID: 1280567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection.
    Vallée E; Azoulay-Dupuis E; Pocidalo JJ; Bergogne-Bérézin E
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1412-7. PubMed ID: 1324644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multicenter study of the clinical efficacy and tolerance of roxithromycin compared to erythromycin ethylsuccinate in lower respiratory tract infections].
    Bertrand A; Jonquet O; Sauvaget J
    Pathol Biol (Paris); 1988 May; 36(5):544-7. PubMed ID: 3043354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythromycin ethylsuccinate, base and acistrate in the treatment of upper respiratory tract infection: two comparative studies of tolerability.
    Saloranta P; Roos L; Elonen E; Allonen H
    J Antimicrob Chemother; 1989 Sep; 24(3):455-62. PubMed ID: 2808197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of a secretolytic agent (bromhexine) on the penetration of erythromycin into bronchial secretions].
    Bergogne-Berezin E; Pierre J; Dournovo P
    Fortschr Med; 1982 Jun; 100(24):1169-71. PubMed ID: 7049878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two oral forms of erythromycin in the treatment of acute respiratory tract infections. A multicentre general practice study.
    Macklin J; Barden R; Coles S
    J Int Med Res; 1989; 17(3):287-94. PubMed ID: 2670633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azithromycin in lower respiratory tract infections.
    Lode H; Schaberg T
    Scand J Infect Dis Suppl; 1992; 83():26-33. PubMed ID: 1336893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythromycin in respiratory tract infection.
    Gould JC
    Scott Med J; 1977 Dec; 22(5):355-9. PubMed ID: 414355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of erythromycin ethylsuccinate in pediatric patients.
    Coyne TC; Shum S; Chun AH; Jeansonne L; Shirkey HC
    J Clin Pharmacol; 1978 Apr; 18(4):194-202. PubMed ID: 632366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group.
    Daniel R
    J Int Med Res; 1991; 19(5):373-83. PubMed ID: 1660824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerance of roxithromycin in comparison with erythromycin stearate in patients with lower respiratory tract infections.
    Paulsen O; Christensson BA; Hebelka M; Ljungberg B; Nilsson-Ehle I; Nyman L; Svensson R; Tüll P; Varga Z
    Scand J Infect Dis; 1992; 24(2):219-25. PubMed ID: 1641600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The pharmacokinetics of 1,000 mg erythromycin lactobionate i. v. in patients with respiratory tract infections (author's transl)].
    Sietzen W
    Infection; 1982; 10 Suppl 2():S99-101. PubMed ID: 7107025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin: an interim analysis.
    Ball AP
    J Int Med Res; 1991; 19(6):446-50. PubMed ID: 1663467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections.
    Bariffi F; Clini V; Ginesu F; Mangiarotti P; Romoli L; Gialdroni-Grassi G
    Infection; 1994; 22(3):226-30. PubMed ID: 7927827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The penetration of macrolides into bronchial secretions.
    Pierre J; Bergogne-Berezin E; Kafe H; Dournovo P
    J Antimicrob Chemother; 1985 Jul; 16 Suppl A():217-20. PubMed ID: 4055550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute bacterial infections of the upper respiratory tract.
    Nadkarni MS; Shah PA; Thakurdesai S
    Curr Med Res Opin; 1977; 4(8):544-54. PubMed ID: 326492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan.
    Hsueh PR; Shyr JM; Wu JJ
    Clin Microbiol Infect; 2006 Mar; 12(3):296-8. PubMed ID: 16451421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Another look at erythromycin.
    Straughan JL
    S Afr Med J; 1978 Apr; 53(14):527-30. PubMed ID: 354037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.